Pharmacologic treatment of ADHD: Road conditions in driving patients to successful outcomes

MedGenMed Medscape General Medicine

Volumn 10, Issue 1, 2008, Pages

  Manos, Michael J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; AMPHETAMINE; ATOMOXETINE; DEXMETHYLPHENIDATE; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO; PSYCHOSTIMULANT AGENT; ADRENERGIC RECEPTOR AFFECTING AGENT; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; PRODRUG; PROPYLAMINE;

ABDOMINAL PAIN; ANOREXIA; ATTENTION DEFICIT DISORDER; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; COST OF ILLNESS; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG ABUSE; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GROWTH DISORDER; GROWTH INHIBITION; HEALTH CARE COST; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; PSYCHOPHARMACOTHERAPY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SLEEP DISORDER; SUBSTANCE ABUSE; SUICIDAL IDEATION; TIC; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CLINICAL PRACTICE;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; DEXTROAMPHETAMINE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRODRUGS; PROPYLAMINES; TREATMENT OUTCOME;

EID: 38949187920     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Bloom B, Dey AN, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2005. Vital Health Stat 10. 2006;10:1-84.
2. Biederman J, Wilens TE, Spencer TJ, et al. Diagnosis and treatment of adults with attention-deficit/hyperactivity disorder. CNS Spectr. 2007;12(suppl 6):1-15.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision. Washington, DC: American Psychiatric Association; 2000:85-93.
4. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000; 105:1158-1170.
5. Pliszka S, for the AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.
6. Katusic SK, Barbaresi WJ, Colligan RC, et al. Case definition in epidemiologic studies of AD/HD. Ann Epidemiol. 2005;15:430-437.
7. Ray GT, Levine P, Croen LA, et al. Attention-deficit/hyperactivity disorder in children: excess costs before and after initial diagnosis and treatment cost differences by ethnicity. Arch Pediatr Adolesc Med. 2006;160:1063-1069.
8. Wolraich ML. Attention-deficit hyperactivity disorder. Semin Pediatr Neuroi. 2006;13:279-285.
9. Pliszka SR, Greenhill LL, Crismon ML et al. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood: attention-deficit/ hyperactivity disorder. Part I. J Am Acad Child Adolesc Psychiatry. 2001;9:908-619.
10. Rappley MD. ADHD. N Engl J Med. 2005;352:165-173.
11. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073-86.
12. Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/ hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics. 2005;115:1734-1746.
13. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2001; 108:1-9.
14. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112-120.
15. Michelson D, Allen AJ, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
16. Gibson AP, Bettinger TL, Patel NC, et al. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother. 2006;40:1134-1142.
17. editorial]. Clinical Psychiatry News. 2006;34:17.
18. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: a phase III, multicenter, randomized, doubleblind, forced-dose, parallel-group study. Clin Ther. 2007;29:450-463.
19. Findling RL, Childress AC, Krishnan S, et al. Long-term efficacy and safety of lisdexamfetamine in school-age children with attention-deficit/ hyperactivity disorder. Poster presented at the 2007 American Psychiatric Association Annual Meeting; San Diego, California; May 19-24, 2007.
20. Ermer JC, Shojael AH, Biederman J, et al. Improved interpatient pharmacokinetic variability of lisdexamfetamine dimesylate compared with mixed amphetamine salts extended release in children aged 6 to 12 years with attention-deficit/hyperactivity disorder. Poster presented at the 2007 American Psychiatric Association Annual Meeting; San Diego, California; May 19-24, 2007.
21. Shojale A, Ermer JC, Krishnan S. Lisdexamfetamine dimesylate as a treatment for ADHD: dosage formulation and pH effects. Poster presented at the 2007 American Psychiatric Association Annual Meeting; San Diego, California; May 19-24, 2007.
22. Greenhill L, Pliszka S, Dulcan M, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:26-49.
23. Swanson J, Greenhill I., Pelham W, et al. Initiating Concerta (OROS methylphenidate HCI) qd in children with attention-deficit hyperactivity disorder. J Clin Res. 2000;3:59-76.
24. Wolraich ML, McGuinn L, Doffing M. Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf. 2007;30:17-26
25. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders?. Findings from a four-year prospective follow-up study. J Am Acad Chid Adolesc Psychiatry. 1997;36:21-29.
26. Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders? J Clin Psychiatry. 2003;11 (suppl 64):9-13.
27. Wilens TE, Biederman J. Alcohol, drugs, and attention-deficit/ hyperactivity disorder: a model for the study of addictions in youth. J Psychopharmacol. 2006;20:580-588.
28. Spencer T, Biederman J, Wilens T. Growth deficits in children with attention deficit hyperactivity disorder. Pediatrics. 1998;102(pt 3):501-506.
29. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113:762-769.
30. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354:1445-1448.
31. Hugtenburg JG, Griekspoor JE, DeBoer I, et al. Methylphenidate: use in daily practice. Pharm World Sci. 2005;27:197-201.
32. Faraone SV, Spencer TJ, Montano CB, et al. Attention-deficit/ hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care. Arch Intern Med. 2004;14:1221-1226.
33. Martins S, Tramontina S, Polanczyk G, et al. Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. Child Adolesc Psychopharmacol. 2004; 14:195-206.
34. Spencer TJ, Faraone SV, Biederman J, et al. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry. 2006;45:527-537.
35. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46:1014-1026.
36. Charach A, Figueroa M, Chen S, et al. Stimulant treatment over-5 years: effects on growth. J Am Acad Child Adolesc Psychiatry. 2006;45:415-421.
37. Pliszka SR, Matthews TL, Braslow KJ, et al. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:520-526.
38. Roessner V, Robatzek M, Knapp G, et al. First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol. 2006;48:616-621.
39. Erenberg G. The relationship between Tourette syndrome, attention deficit hyperactivity disorder, and stimulant medication: a critical review. Semin Pediatr Neurol. 2005; 12:217-221.
40. Biederman J, Wilens T, Mick E, et al. Psychoactive substance use in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;52:1652-1658.
41. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1997;36:21-29.
42. Lambert N, Hartsough C. Prospective study of tobacco smoking and substance dependence among samples of ADHD and non-ADHD subjects. J Learn Disabil. 1998;31:533-544.
43. Chilcoat HD, Breslau N. Pathways from ADHD to early drug use. J Am Acad Child Adolesc Psychiatry. 1999;38:1347-1354.
44. Burke JD, Loeber R, Lahey BB. Which aspects of ADHD are associated with tobacco use in early adolescence? J Child Psychol Psychiatry. 2001;42:493-502.
45. Patemite CE, Loney J, Salisbury H, et al. Childhood inattention-overactivity, aggression, and stimulant medication history as predictors of young adult outcomes. J Child Adolesc Psychopharmacol. 1999;9:169-184.
46. U.S. Food and Drug Administration. FDA issues public health advisory on Strattera. (atomoxetine) for attention deficit disorder. FDA Press Release P0-65. http://www.fda.gov/bbs/topics/NEWS/2005/NEW01237.html. Accessed May 11, 2007.
47. U.S. Food and Drug Administration. Patient Information Sheet: atomoxetine (marketed as Strattera). http://www.fda.gov/cder/drug/ InfoSheets/patient/AtomoxetinePT.htm. Accessed September 20, 2007.
48. U.S. Food and Drug Administration. FDA asks attention-deficit hyperactivity disorder (ADHD) drug manufacturers to develop patient medication guides. February 21, 2007. http://www.fda.gov/cder/drug/ infopage/ADHD/default.htm. Accessed May 11, 2007.
49. U.S. Food and Drug Administration. FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events. FDA News P07-26. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01568:html. Accessed May 10, 2007.
50. Hechtman L. Long-term treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Psychiatry Rep. 2006;8:398-408.
51. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716-723.
52. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:1792-1798.
53. Biederman J, Arnsten AF, Faraone SV, et at. New developments, in the treatment of ADHD. J Clin Psychiatry. 2006;67:148-159.
54. Noorbala AA, Akhondzadeh S. Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy. Arch, Iran Med. 2006;9:374-80.
55. Wilens TE, Verlinden MH, Adler LA, et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-defici/ hyperactiviy disorder in adults: results of a pilot study. Biol Psychiatry. 2006;59:1065-1070.
56. Swearingen D. Pennick M. Shojaei A. et al. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther. 2007;29:617-625.
57. Concerta package insert. McNeil Pediatrics. March 2007. Available at: http://www.concerta.net/concerta/assets/prescribing_info.pdf.
58. Metadate CD package insert. Celitech Pharmaceuticals, Inc. June 2005. Available at: http://www.theodora.com/drugs/ metadate_cd_capsules_ucb.html#PATIENT_PACKAGE_INSERT.
59. Focalin full prescribing information. Novartis Pharmaceuticals. April 2007. Available at: http://www.pharma.us.novartis.com/product/pi.jsp
60. Adderall XR package insert. Shire LLC.
61. Strattera package insert. Eli Lilly and Company. 2007. Available at: http://pi.lilly.com/us/strattera-pl.pdf
62. Ritalin LA package insert. April 2007. Available at: http://www.pharma.us.novartis.com/product/pi.jsp
63. Focalin XR full prescribing information. Novartis Pharmaceuticals. April 2007. Available at: http://www.pharma.us.novartis.com/product/pi.jsp.
64. Daytrana full prescribing information. Shire Pharmaceuticals Ireland Limited. October 2007. Available at: http://www.daytrana.com/Consumers/ PDFs/DaytranaPrescribinginfo.pdf.
65. Vyvanse full prescribing information. Shire US, Inc. February 2007. Available at: https://www.vyvanse.com/pdf/prescribing_information.pdf